تداخلات لينزوليد

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (نشرة أبراكلونيدين، موانع الاستعمال)

Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI) [see Drug Interactions (7) ] . (نشرة أتوموكسيتين، موانع الاستعمال)

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (نشرة أزرق الميثيلين، التداخلات الدوائية)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

…Precautions (5.2) ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see Warnings and Precautions (5.5) ] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [ see Warnings and Precautions (5.7), Drug Interactions (7) ] • Known or suspected gastrointestinal obstruction,… (نشرة البلادونا والأفيون، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (نشرة أمفيتامين، موانع الاستعمال)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (نشرة أمفيتامين وديكستروأمفيتامين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (نشرة أوكسيكودون، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.2)]. (نشرة أوكسيكودون وباراسيتامول، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (نشرة أوكسيمورفون، التداخلات الدوائية)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (نشرة أوندانسيترون، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

…respiratory depression ( see WARNINGS ). acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment ( see WARNINGS ). concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days ( see WARNINGS ). known or suspected gastrointestinal obstruction, including paralytic ileus ( see WARNINGS… (نشرة باراسيتامول وكودايين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

…uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (see PRECAUTIONS – Drug Interactions ). (نشرة بروميثازين وديكستروميثورفان، موانع الاستعمال)

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [ see Warnings and Precautions (5.16) , Drug Interactions (7.6) ]. (نشرة بروميثازين وكودايين، موانع الاستعمال)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (نشرة بنزفيتامين، موانع الاستعمال)

Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.8), Warnings and Precautions (5.4), and Drug Interactions (7.6)] . (نشرة بوبروبيون، موانع الاستعمال)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (نشرة بوبرينورفين، التداخلات الدوائية)

Examples: phenelzine, tranylcypromine, linezolid Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

…Precautions ( 5.2 )] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.10 )] • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.11 ), Drug Interactions ( 7 )] • Known or suspected gastrointestinal obstruction,… (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، موانع الاستعمال)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome. (نشرة بوسبيرون، موانع الاستعمال)

Concomitant Use of DEMEROL Injection with Monoamine Oxidase (MAO) Inhibitors Concomitant use of DEMEROL Injection with monoamine oxidase (MAO) inhibitors can result in coma, severe respiratory depression, cyanosis, and hypotension. (نشرة بيثيدين، تحذير مؤطر)

…suspected paralytic ileus [see Warnings and Precautions (5.12) ] Hypersensitivity to tapentadol (e.g., anaphylaxis, angioedema) or to any other ingredients of the product [see Adverse Reactions (6.2) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Drug Interactions (7) ] Significant respiratory depression ( 4 ) (نشرة تابنتادول، موانع الاستعمال)

Intervention: RALDESY is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4) , Dosage and Administration ( 2.3 , 2.4) , and Warnings and Precautions (5.2) ]. (نشرة ترازودون، التداخلات الدوائية)

…gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.16) ] Hypersensitivity to tramadol (e.g., anaphylaxis) [see Warnings and Precautions (5.17) , Adverse Reactions (6) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7) ] Children younger than 12 years of age. (نشرة ترامادول، موانع الاستعمال)

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days [see Drug Interactions (7) ]. (نشرة ترامادول وباراسيتامول، موانع الاستعمال)

Need for Emergency Treatment with Contraindicated Drugs If in the absence of therapeutic alternatives emergency treatment with a contraindicated product (e.g., linezolid, intravenous methylene blue, direct-acting sympathomimetic drugs such as epinephrine) becomes necessary and cannot be delayed, discontinue tranylcypromine sulfate tablets as soon as possible… (نشرة ترانيلسيبرومين، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Taking monoamine oxidase inhibitors (MAOIs). (نشرة تيترابينازين، موانع الاستعمال)

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (نشرة دروكسيدوبا، التداخلات الدوائية)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (نشرة دوكسيلامين وبيريدوكسين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (نشرة ديثيل بروبيون، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (نشرة ديفينوكسيلات وأتروبين، التداخلات الدوائية)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (نشرة ديكستروأمفيتامين، موانع الاستعمال)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (نشرة ديكستروميثورفان، التحذيرات)

Use with an MAOI or within 14 days of stopping an MAOI. (نشرة ديكستروميثورفان وكينيدين، موانع الاستعمال)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (نشرة ديكسكلورفينيرامين، موانع الاستعمال)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (نشرة ديكسميثيل فينيدات، موانع الاستعمال)

Taking monoamine oxidase inhibitors (MAOIs). (نشرة ديوتيترابينازين، موانع الاستعمال)

John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor ( 4 ) (نشرة راساجيلين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (نشرة زيبراسيدون، موانع الاستعمال)

…uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (نشرة سيبروهيبتادين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of a MAO inhibitor. (نشرة سيكلوبنزابرين، موانع الاستعمال)

MAO Inhibitors ZELAPAR is contraindicated for concomitant use with other drugs in the MAOI class or other drugs that are potent inhibitors of monoamine oxidase (including linezolid, an oxazolidinone antibacterial, which also has reversible nonselective MAO inhibition activity) because of the increased risk for hypertensive crisis [see Contraindications (4) and… (نشرة سيليجيلين، التداخلات الدوائية)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (نشرة غرانيسيترون، التحذيرات والاحتياطات)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (نشرة فالبينازين، التداخلات الدوائية)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

Starting TRINTELLIX in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) ] . (نشرة فورتيوكسيتين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Qelbree is contraindicated in patients: receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis [see Drug Interactions (7.1) ] . receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic… (نشرة فيلوكسازين، موانع الاستعمال)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (نشرة فينترمين، موانع الاستعمال)

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (نشرة فينترمين وتوبيرامات، موانع الاستعمال)

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (نشرة فينديميترازين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. (نشرة لينزوليد، موانع الاستعمال)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (نشرة كاربامازيبين، موانع الاستعمال)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (نشرة كاربيدوبا، موانع الاستعمال)

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (نشرة كاربيدوبا وليفودوبا، موانع الاستعمال)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (نشرة كاربيدوبا وليفودوبا وإنتاكابون، موانع الاستعمال)

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (نشرة كاربينوكسامين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ), Drug Interactions ( 7 )]. (نشرة كودايين، موانع الاستعمال)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (نشرة ليسديكسامفيتامين، موانع الاستعمال)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (نشرة ليفودوبا، موانع الاستعمال)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.9 ) and Drug Interactions ( 7 )]. (نشرة مورفين، موانع الاستعمال)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ميثادون، التحذيرات والاحتياطات)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (نشرة ميثامفيتامين، موانع الاستعمال)

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (نشرة ميثيل دوبا، موانع الاستعمال)

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (نشرة ميثيل فينيدات، موانع الاستعمال)

Avoid use of MAO inhibitors or linezolid with midodrine. (نشرة ميدودرين، التداخلات الدوائية)

REMERON/REMERONSolTab is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (نشرة ميرتازابين، موانع الاستعمال)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) MAOI (e.g., phenelzine, tranylcypromine, linezolid) interactions with opioids may manifest as serotonin syndrome [see PRECAUTIONS; Drug Interactions ] or opioid toxicity (e.g., respiratory depression, coma [see WARNINGS ]). (نشرة نالبوفين، التداخلات الدوائية)

Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated [see Dosage and Administration (2.4) , Drug Interactions (7.1) ] Known allergy to bupropion, naltrexone or any other component of CONTRAVE. (نشرة نالتريكسون وبوبروبيون، موانع الاستعمال)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (نشرة لينزوليد، التحذيرات والاحتياطات)

Severe hyperthermia and seizures, sometimes fatal, have been reported in association with the combined use of tricyclic antidepressants and MAOIs. (نشرة نيفازودون، التحذيرات)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.3) ] . (نشرة هيدروكودون، التداخلات الدوائية)

If urgent use of an opioid is necessary with MAOIs such as phenelzine, tranylcypromine, linezolid, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة هيدروكودون وإيبوبروفين، التداخلات الدوائية)

The use of hydrocodone bitartrate and acetaminophen tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. (نشرة هيدروكودون وباراسيتامول، التداخلات الدوائية)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions ( 5.3 )]. (نشرة هيدرومورفون، التداخلات الدوائية)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (نشرة إستازولام، التداخلات الدوائية)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (نشرة إيزوفلوران، التداخلات الدوائية)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (نشرة لينزوليد، التحذيرات والاحتياطات)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (نشرة بروميثازين، التداخلات الدوائية)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors may result in increased hypotension. (نشرة بريمونيدين، التداخلات الدوائية)

Monoamine oxidase inhibitors may result in increased hypotension. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (نشرة بوتالبيتال وباراسيتامول، التداخلات الدوائية)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (نشرة دروبيريدول، التحذيرات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (نشرة ديازيبام، التداخلات الدوائية)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (نشرة ديسيكلومين، التداخلات الدوائية)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (نشرة ديفينهيدرامين، التداخلات الدوائية)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (نشرة سكسينيل كولين، التداخلات الدوائية)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (نشرة سيفوفلوران، التداخلات الدوائية)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (نشرة لينزوليد، التحذيرات والاحتياطات)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (نشرة كارفيديلول، التداخلات الدوائية)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (نشرة كلونازيبام، التداخلات الدوائية)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (نشرة كليماستين، التداخلات الدوائية)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (نشرة كوكايين، التداخلات الدوائية)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (نشرة ميتوبرولول، التداخلات الدوائية)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

…administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7)… (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (نشرة لينزوليد، التحذيرات والاحتياطات)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (نشرة هيدرالازين، التداخلات الدوائية)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (نشرة لينزوليد، التحذيرات والاحتياطات)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (نشرة إنتاكابون، التحذيرات)

…Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI 0.970, 2.098]. (نشرة لينزوليد، التحذيرات والاحتياطات)

Commonly used serotonergic agents include serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine. (نشرة لينزوليد، التحذيرات والاحتياطات)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (نشرة بروبرانولول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (نشرة تولكابون، التحذيرات)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (نشرة ديفينوكسين وأتروبين، التداخلات الدوائية)

…Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI… (نشرة لينزوليد، التحذيرات والاحتياطات)

…Patients With Catheter-Related Bloodstream Infections, Including Those With Catheter-Site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426,… (نشرة لينزوليد، التحذيرات والاحتياطات)